Related Experiment Videos
Ceftriaxone therapy for staphylococcal osteomyelitis: a review
B J Guglielmo1, A D Luber, D Paletta
1Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, CA 94143-0622, USA. bjg@itsa.ucsf.edu
Summary
Ceftriaxone shows promise for treating Staphylococcus aureus osteomyelitis, particularly in ambulatory settings. While less potent than other agents, it achieved a high cure rate in this study.
Area of Science:
- Infectious Diseases
- Orthopedic Surgery
- Pharmacology
Background:
- Osteomyelitis, a bone infection, often requires prolonged antibiotic treatment.
- Staphylococcus aureus is a common causative agent of osteomyelitis.
- Ceftriaxone is a third-generation cephalosporin with broad-spectrum activity.
Purpose of the Study:
- To evaluate the efficacy of ceftriaxone in treating osteomyelitis caused by Staphylococcus aureus.
- To compare ceftriaxone treatment outcomes with other antimicrobial agents.
Main Methods:
- Retrospective analysis of 31 patients diagnosed with Staphylococcus aureus osteomyelitis.
- Treatment groups included 22 patients receiving ceftriaxone and 9 receiving alternative agents.
- Outcomes assessed included treatment success (cure) and failure.
Main Results:
- Ceftriaxone treatment resulted in a cure for 17 out of 22 patients.
- Treatment failures were linked to chronic osteomyelitis and the presence of necrotic bone or hardware.
- Ceftriaxone demonstrated effectiveness in ambulatory treatment settings.
Conclusions:
- Ceftriaxone is a viable option for treating Staphylococcus aureus osteomyelitis, especially in outpatient management.
- Careful patient selection is advised, considering factors like chronicity and hardware presence.
- Further research may explore optimal dosing and duration for ceftriaxone in osteomyelitis.